201 related articles for article (PubMed ID: 35150408)
1. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
Tsukamoto S; Takahama T; Mavrogenis AF; Tanaka Y; Tanaka Y; Errani C
Musculoskelet Surg; 2023 Mar; 107(1):7-18. PubMed ID: 35150408
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
[TBL] [Abstract][Full Text] [Related]
3. Oral vinorelbine in young patients with desmoid-type fibromatosis.
Kornreich L; Orbach D; Nicolas N; Brisse HJ; Berlanga P; Defachelles AS; Mansuy L; Verite C; Saumet L; Karanian M; Corradini N
Tumori; 2023 Oct; 109(5):511-518. PubMed ID: 37114926
[TBL] [Abstract][Full Text] [Related]
4. Desmoid tumors: who, when and how to treat?
Mikhael R; Smith M; Tzanis D; Watson S; Miah AB; Bonvalot S
Curr Opin Oncol; 2022 Jul; 34(4):335-341. PubMed ID: 35837705
[TBL] [Abstract][Full Text] [Related]
5. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.
Palassini E; Frezza AM; Mariani L; Lalli L; Colombo C; Fiore M; Messina A; Casale A; Morosi C; Collini P; Stacchiotti S; Casali PG; Gronchi A
Cancer J; 2017; 23(2):86-91. PubMed ID: 28410293
[TBL] [Abstract][Full Text] [Related]
6. Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Gounder MM; Lefkowitz RA; Keohan ML; D'Adamo DR; Hameed M; Antonescu CR; Singer S; Stout K; Ahn L; Maki RG
Clin Cancer Res; 2011 Jun; 17(12):4082-90. PubMed ID: 21447727
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.
Shimizu K; Kawashima H; Kawai A; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Oct; 50(11):1274-1281. PubMed ID: 32700733
[TBL] [Abstract][Full Text] [Related]
8. Therapy of desmoid tumors and fibromatosis using vinorelbine.
Weiss AJ; Horowitz S; Lackman RD
Am J Clin Oncol; 1999 Apr; 22(2):193-5. PubMed ID: 10199460
[TBL] [Abstract][Full Text] [Related]
9. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.
Braggio D; Koller D; Jin F; Siva N; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Strohecker AM; Lev D; Pollock RE
Cancer; 2019 Aug; 125(15):2693-2703. PubMed ID: 30980399
[TBL] [Abstract][Full Text] [Related]
10. [Low-dose methotrexate combined with vinorelbine for inoperable desmoid tumor: efficacy and the prognostic factors].
Fan Z; Li S; Fang Z; Liu J; Bai C; Xue R; Zhang L; Gao T
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jan; 36(1):39-43. PubMed ID: 26806736
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
12. Desmoid Fibromatosis: Management in an Era of Increasing Options.
Ratan R; Roland CL; Bishop AJ
Curr Oncol Rep; 2021 Mar; 23(4):41. PubMed ID: 33719012
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose chemotherapy with methotrexate and vinblastine for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.
Shimizu K; Hamada S; Sakai T; Koike H; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Apr; 50(4):419-424. PubMed ID: 31845730
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
15. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
16. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
17. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate and Vinblastine or Vinorelbine Remain Useful Treatments for Desmoid-Type Fibromatosis 30 Years Later.
Schuetze SM
Cancer J; 2017; 23(2):92-94. PubMed ID: 28410294
[No Abstract] [Full Text] [Related]
19. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
Ravaioli A; Nicoletti S; Tamburini E; Papi M
J Cancer Res Clin Oncol; 2009 Feb; 135(2):325-6. PubMed ID: 18825412
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Papadopoulos S; Koulouris P; Royer-Chardon C; Tsoumakidou G; Dolcan A; Cherix S; Matter M; Omoumi P; Digklia A
Front Endocrinol (Lausanne); 2022; 13():794512. PubMed ID: 35399933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
